Kornimate/medical-research-clean huggingface dataset:
efficacy and safety of nitrofurantoin in the treatment of uncomplicated urinary tract infections in adults

Conditions: Urinary Tract Infection

Summary: the study aims to investigate bacteriological efficacy of a nitrofurantoin formulation given twice daily for seven days in the treatment of adult patients with microbiologically confirmed uncomplicated urinary tract infection. additional study objectives are to evaluate clinical efficacy as well as safety and tolerability of the nitrofurantoin formulation.


Eligibility criteria:
inclusion criteria: * non-pregnant women and men aged above 18 years old * presence of ≥ 2 signs or symptoms suggestive of a uti (dysuria, urinary frequency, urgency, suprapubic pain) with onset 10 days before enrollment * asymptomatic patients with available positive urine culture * pyuria defined as positive leucocyte esterase (le) test with any color change after two minutes * collection of clean-voided midstream urine sample for culture and susceptibility testing to confirm bacteriuria * normal renal function (defined as blood creatinine \< 1.4 mg/100 ml) * able to take oral medication on an outpatient basis * written informed consent before enrollment exclusion criteria: * suspicion of complicated uti (presence of fever above 38°c, flank pain, known urologic structural abnormality) or prostatitis * negative urine dipslide results (uropathogen \< 100000 cfu (colony-forming units)/ml) or presence of nitrofurantoin resistant isolate uropathogens or mixed cultures of more than two isolates * symptoms of uti within the past 4 weeks * evidence of predisposing factor to uti (e.g. calculi, stricture, primary renal disease like polycystic renal diseases and neurogenic bladder) * medical history of anaemia, complicated diabetes mellitus, peripheral neuropathy, vitamin b deficiency, renal insufficiency, other significant renal, hepatic or lung diseases * medical history of glucose-6-phosphate dehydrogenase deficiency (g6pd) * electrolytes disorders * pregnant, breast-feeding women or not using medically accepted, effective method of birth control * history of nitrofurantoin hypersensitivity * use of systemic bacteriological agent within 48 hours before enrollment

Keywords: urinary tract infection nitrofurantoin
a master protocol of multiple interventions for the treatment of adults with moderate-to-severe atopic dermatitis.

Conditions: Atopic Dermatitis

Summary: this platform trial is designed to enable the investigation of many interventions for ad by means of the introduction of new interventional specific addenda (isas) over time. at the inception of this platform trial, at least 1 isa will be available. additional isas will be added to the platform trial over time.


Eligibility criteria:
inclusion criteria: * present with a diagnosis of atopic dermatitis (ad) at least 12 months prior to screening * eczema area and severity index (easi) score ≥12 * validated investigator global assessment ad (viga-ad) score ≥3 * ≥10% of bsa involvement (per easi bsa) * are candidates for systemic therapy, and have a history, documented by a physician and/or the investigator, of inadequate response to existing topical medications within 6 months preceding screening. exclusion criteria: * have a history of eczema herpeticum: * any episode within 12 months prior to screening, or * 2 or more episodes during lifetime * are currently experiencing or have a history of concomitant skin conditions other than ad, for example, psoriasis or cutaneous lupus, that, in the opinion of the investigator, would interfere with evaluations of the effect of study intervention on ad. * are currently experiencing or have a history of erythrodermic, refractory, or unstable skin disease which requires frequent hospitalizations or iv treatment and, in the opinion of the investigator, could interfere with study participation * are currently experiencing a skin infection that requires treatment with, or is currently being treated with, topical or systemic antibiotics. note: participants who fail screening due to this criterion should not be rescreened until at least 4 weeks after screen failure and at least 2 weeks after resolution of the infection.
phase ii study of golidocitinib and benmelstobart in patients with r/r enktl (jackpot50)

Conditions: Natural Killer T-cell Lymphoma

Summary: this is a prospective, single-arm, multicenter, phase ii clinical trial to evaluate the efficacy and safety of golidocitinib and benmelstobart combination treatment in patients with relapsed or refractory extranodal natural killer/t cell lymphoma.


Eligibility criteria:
inclusion criteria: 1. subjects fully understand and voluntarily participate in this study and sign informed consent. 2. pathologically confirmed extranodal natural killer/t cell lymphoma (enktl). 3. age ≥18, no gender limitation. 4. treatment failure to at least one line of asparaginase-based therapy. 5. eastern cooperative oncology group performance status of 0-2 6. expected survival ≥ 3 months. 7. at least one measurable lesion that meets lugano 2014 criteria. 8. sufficient organ function. exclusion criteria: 1. invasive nk-cell leukemia or nktcl that has progressed to leukemia. 2. accompanied by hemophagocytic lymphohistiocytosis. 3. nktcl with central nervous system invasion. 4. previously treated with jak inhibitors. 5. the patients have contraindications to any drug in the combined treatment. 6. patients with the infection of human immunodeficiency virus (hiv) and/or acquired immunodeficiency syndrome. 7. inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect the absorption of the study drug. 8. pregnant and lactating women and subjects of childbearing age who do not want to use contraception. 9. mentally ill persons or persons unable to obtain informed consent. the investigators think that the patient is not suitable for the study.
new lung ventilation strategies guided by transpulmonary pressure in vv-ecmo for severe ards

Conditions: Respiratory Distress Syndrome, Adult

Summary: extracorporeal membrane oxygenation (ecmo) has been widely used in patients with severe acute respiratory distress syndrome (ards). but how to choose mechanical ventilation strategy is still not clear for severe ards patients supported by ecmo. our previous work found that, compared to the traditional "lung rest" strategy, transpulmonary pressure guide new lung ventilation strategy can better maintain lung volume reduction lung collapse, atelectasis occurs. the severe ards patients receiving ecmo therapy were randomized divided into a new ventilation strategy group and the conventional ventilation strategy group. the new ventilation strategy is transpulmonary pressure guide ventilator setting method, and the conventional ventilation strategy is extracorporeal life support organization (elso) guide ventilation method. compare the difference between the two groups of patients in lung injury, and explore the lung protection mechanism of new lung ventilation strategies guided by transpulmonary pressure. our research group considered that transpulmonary pressure guide new lung ventilation strategy can provide more effective lung protection. and it will be further used in clinical work.


Eligibility criteria:
inclusion criteria: * ards cause reversible; * pure oxygen is given, but pao2/fio2\<80; * p(a-a)o2\>600mmhg; * murray score≥3.0; * ph\<7.2; exclusion criteria: * peak inspiratory pressure\>30cmh2o; * high fio2\>0.8; * ventilation\>7 days; * contraindication to heparinization; * non-reversible central nervous system injury * chronic disease with a short life expectancy

Keywords: extracorporeal membrane oxygenation
polestar trial - an international multi-center early discharge tavi program

Conditions: Aortic Valve Stenosis

Summary: an international multi-center prospective observational study to address safety and feasibility of an early discharge protocol in patients with symptomatic severe aortic stenosis who are eligible for transfemoral tavi with the boston scientific acurate neo aortic bioprosthesis transcatheter heart valve.

in this international multi-center prospective observational study, 250 patients with severe symptomatic aortic stenosis (as) and eligibility for transfemoral tavi with acurate neo bioprosthesis, will be pre-procedurally selected for participation in an early discharge protocol in which patients are discharged within 48 hours after uncomplicated tavi.

Eligibility criteria:
inclusion criteria: * eligible for acurate neo valve implantation * patient agrees to follow-up duration * patient is able to understand and sign written informed consent exclusion criteria: * bmi \> 35 * pregnancy cardiac * moderate to severely impaired left ventricular ejection fraction (lvef \<35%) * mitral regurgitation \> moderate * pulmonary hypertension (spap \> 60mmhg) * no complex coronary artery disease * untreated high degree av-block or rbbb pulmonary * copd gold \> 2 kidney function * gfr \< 35ml/min frailty * inappropriate social support and/or (familial) care * patient is walking aid dependent tavi strategy * presence of severe peripheral artery disease * transfemoral approach not possible follow up * inability to adhere to follow-up

Keywords: tavi tavr early discharge acurate neo
percutaneous fixation of acute scaphoid fractures

Conditions: Scaphoid Fracture

Summary: percutaneous trans-trapezial fixation of acute scaphoid fractures by herbert screw

aim of the work: to assessment outcomes of percutaneous trans-trapezial fixation of acute scaphoid fracture. operative technique: anesthesia: carried out under general anesthesia or brachial plexus block and under tourniquet control. position: supine. approach: percutaneous trans-trapezial fixation of acute scaphoid fracture. recording any intraoperative complication that may affect the result. postoperative follow up: short arm circular cast including the thumb will be applied. after 3 weeks, cast will be removed and exercises will start.

Eligibility criteria:
inclusion criteria: * - acute stable non displaced waist fracture (a2). * acute unstable oblique distal third (b1). * acute unstable displaced waist (b2). * acute un stable fracture dislocation (b4). * acute un stable comminuted fracture (b5). exclusion criteria: * - acute stable fracture tubercle (a1). * acute unstable fracture proximal pole (b3). * delayed union fracture (c). * established non-union fracture includes fibrous (d1) and sclerotic (d2). * bilateral fractures because of possible interference with postoperative grip strength measurement.
recovery and symptom relief following percutaneous ablation of abdominal wall endometriosis

Conditions: Endometriosis

Summary: to determine the characteristics of recovery and symptom relief following ablation of abdominal wall endometriosis.

the purpose of this study is to characterize the recovery and symptom relief following cryoablation of abdominal wall endometriosis. patients undergoing clinically indicated ablation of abdominal wall endometriosis will receive an endometriosis-specific symptom survey (endometriosis health profile - 30) prior to ablation and then at 3-, 6-, 12-, and 24-months following treatment. a 2 question survey related to pain at the treatment site will also be administered prior to ablation and then at 1-, 7-, and 30-days after ablation.

Eligibility criteria:
inclusion criteria: * undergoing ablation for abdominal wall endometriosis. exclusion criteria: * decline to participate in research.

Keywords: abdominal wall endometriosis
performing a low-dose, whole-body angiography as the first element of an imaging assessment following stroke / tia

Conditions: Stroke; Ischemic Attack, Transient

Summary: the main objective of this study is to compare two post-stroke/tia (transient ischemic attack) imaging strategies in terms of the number of clinically important (i.e. requiring specific treatment according to current recommendations) lesions detected. the first strategy is the current/usual strategy in each participating centre and the second strategy consists in starting the post-stroke/tia imaging assessment by a whole-body, low-dose angiography and subsequently resorting to elements of the usual strategy if required.

the secondary objectives are: a. to compare the patient pathways between the two arms in terms of time to diagnosis, and duration of hospitalization. b. to compare the consumption of imaging exams (number and type) and total body irradiation between the two arms. c. to compare the diagnostic efficiency between the two arms in terms of detection of predefined lesions, and performance ratios. d. to study the thickness of the left atrial wall as a risk factor for permanent atrial fibrillation. e. to compare the distribution of suspected neoplasms between the two groups, as well as the number of detected incidentalomas. f. to compare the survival and the incidence of new cardiovascular events between the two arms at 12 months and 36 months. g. to compare the quality of life between the two arms at 12 months and 36 months.

Eligibility criteria:
inclusion criteria: * the patient was informed about the implementation of the study, its objectives, constraints and patient rights * the patient has given free and informed consent and signed the consent * patient affiliated with or beneficiary of a health insurance plan * patient available for 36 months of follow-up * the patient has had a stroke (within the past 10 days, diagnosis confirmed by mri with a diffusion sequence) or transient ischemic attack (within the past 10 days, abcd2 score greater than 3) without haemorrhage exclusion criteria: * the patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study. * patient under guardianship or judicial protection * refusal to sign the consent * inability to correctly inform the patient or his/her trusted person about the study * the patient is pregnant, parturient, or breastfeeding * the patient has a contraindication for a treatment used in this study * known allergy to contrast medium or severe allergy to iodine * known active malignancy or history of cancer treatment * the patient has already undergone a full body scanner in the previous three months * renal failure with creatinine clearance below 60 ml / min * monoclonal immunoglobulin * history of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia) * emergency situations that hamper the planned course of the study
evaluation of "tent-pole" grafting technique for reconstruction of mandibular ridge vertical defects

Conditions: Jaw Deformity

Summary: the aim of this study is to evaluate clinically and radio-graphically the efficiency of "tent- pole "grafting technique for reconstruction of anterior or posterior mandibular ridge defects using synthetic bone graft and platelet rich fibrin (prf) membrane.

various techniques have been described for the reconstruction of large vertical defects before implant placement . in this study we assessed the efficacy of tenting the periosteum and soft tissue matrix with titanium screws maintaining a space for the graft material in order to augment large vertical defects of mandibular ridge (anterior or posterior region) using data from 12 patients . after 6 months we assessed the increase in bone height and density.

Eligibility criteria:
inclusion criteria: * patients with missing lower tooth or teeth and have a related large vertical bony defect . * patients with about 7mm residual bone hight and requiring about 5 mm increase in the vertical height of the mandibular alveolar ridge for future prosthetic rehabilitation. * patients with an acceptable oral hygiene and willing to improve it exclusion criteria: * presence of infection or local lesions. * parafunctional habits. * current chemotherapy or radiotherapy. * heavy smokers. * alcohol or drug abuse. * medically compromised patients with diseases that affect passively the clinical procedure or result.
a study to assess bms-986453 in participants with relapsed and/or refractory multiple myeloma

Conditions: Relapsed and/or Refractory Multiple Myeloma

Summary: the purpose of this study is to assess bms-986453 in participants with relapsed and/or refractory multiple myeloma (rrmm).


Eligibility criteria:
inclusion criteria: * participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease. * participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry. * participants in part a and part b cohort 1 must have received at least 3 prior anti-myeloma treatment regimens, including a proteasome inhibitor and immunomodulatory agent. * participants must have an eastern cooperative oncology group (ecog) performance status of 0 or 1. * participants must have adequate organ function. exclusion criteria: * participants must not have any known active or history of central nervous system (cns) involvement of multiple myeloma. * participants must not have active or history of plasma cell leukemia, waldenstrom's macroglobulinemia, poems (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis. * participants must not have a history or presence of clinically significant cns pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, parkinson's disease, or cerebellar disease, or presence of clinically active psychosis. other protocol-defined inclusion/exclusion criteria apply

Keywords: dual targeting bcmaxgprc5d gprc5dxbcma bms-986453 car t cart multiple myeloma relapsed and/or refractory
complete lifestyle medicine intervention program

Conditions: High Cholesterol; Diabetes; Obesity; Hypertension; Heart Diseases

Summary: this project will use a mixed design and will be conducted at the west parry sound health centre. based on similar studies there is an expected 10% drop-out rate so 20 participants per group will be invited to aim to have 15 finish. total participants invited over the two-year study will be 40. the participants will be followed over a complete 6-month lifestyle medicine intervention program (clip) involving a collaboration between physicians, health coach, registered dietitians, and kinesiology. the clip will cover the 6 pillars of lifestyle medicine in 12-14 fundamentals of lifestyle medicine group classes.

participants will have the option of a hybrid platform to ensure equal access. participants will attend (virtually or in person) a weekly lecture on lifestyle medicine pillars for 16 weeks followed by a weekly exercise program for 8 weeks. this program was inspired by the research team of albert et al 2022. the eligibility criteria for participation in the lifestyle medicine program include adults with chronic diseases such as * prediabetes, * type 2 diabetes, * pre-hypertension, * systemic hypertension, * heart disease, dyslipidemia, * and/or excess weight (bmi ≥ 25 (42)). patients will be invited through referral by their physicians, email by local heart disease and diabetes foundation, mail-out by nurse practitioner and community health teams. metrics: participants will be evaluated using validated pre-and post intervention validated surveys provided by the american college of lifestyle medicine, the lifestyle assessment short form. added to the validated survey included questions on demographic characteristics including gender, age, race and ethnicity, language use, education, health insurance marital status. participants will complete the well-being assessment and lifestyle medicine survey (american college of lifestyle medicine)

Eligibility criteria:
inclusion criteria: * prediabetes, * type 2 diabetes, * pre-hypertension, * systemic hypertension, * heart disease, dyslipidemia, * and/or excess weight (bmi ≥ 25 (42)). exclusion criteria: * healthy participants
a study investigating the effects of activamp on body weight, fat loss, and metabolic markers in healthy overweight participants

Conditions: Body Weight

Summary: the purpose of this study is to determine the effects of activamp, a product containing gynostemma pentaphyllum extract, on body weight, fat loss and metabolic markers in healthy overweight adults.


Eligibility criteria:
inclusion criteria: * healthy male or female 21-55 years of age * bmi of 25.0 kg/m2 to 29.9 kg/m2 (± 1.0kg/m2) * must have negative urine pregnancy test at screening * female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. * subject agrees to maintain their normal level of physical activity throughout the study * weight has been stable for the last 3 months * subject agrees to comply with study procedures * healthy as determined by laboratory results, medical history and physical exam * subject agrees not to participate in structured activity including resistance training and aerobic exercise more than 3 times per week * has given voluntary, written, informed consent to participate in the study exclusion criteria: * women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial * subject who have experienced a greater than 10% variation in body weight in the past 3 months * history of, or current diagnosis of any major diseases of the cardiovascular, hepatic, renal, gastrointestinal, pulmonary or endocrine systems * history of surgery for weight loss (including gastric bypass or lapband) * history of conditions that could interfere with the test product or impede its absorption such as gastrointestinal disease (crohn's disease) or experienced surgery (caecum or enterocele surgery) * subjects diagnosed with type ii diabetes * subjects with active cancer (excluding basal cell carcinoma) * subjects with active eating disorders * subjects who have undergone anti-psychotic drug therapy within the past 2 months * use of prescription or over the counter medications known to affect weight within 3 weeks of randomization or during the study * use of any supplements, programs, or meal replacement products, other than those provided, intended to alter body weight within two weeks of screening or during the course of the study * use of illicit drugs or history of drug or alcohol abuse within the past 6 months * currently having more than 2 standard alcoholic drinks per day * participation in a clinical research trial within 30 days prior to randomization * allergy or sensitivity to test article ingredients * individuals who are cognitively impaired and/or who are unable to give informed consent * abnormal lab test results or any other medical or psychological condition which in the investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject

Keywords: activamp gynostemma pentaphyllum body weight fat loss metabolic markers overweight participants dxa ampk
effect of turner syndrome on number sense

Conditions: Turner Syndrome

Summary: this study evaluates approximate number sense (ans) in children, adolescents, and adult women with turner syndrome compared to age-matched healthy peers. one primary aim of this project is to assess the effectiveness of an online ans training tool in enhancing complex mathematics ability. participants will undergo weekly training sessions in their own home. half of the participants will complete 2 training sessions a week for 8 weeks, and the second half will complete 1 training session for 8 weeks.


Eligibility criteria:
inclusion criteria: * children, adolescents, and adult women with turner syndrome. * healthy controls. * normal or corrected to normal vision. exclusion criteria: * major psychiatric or developmental disorder (e.g., bipolar disorder, major depression, psychotic disorders, intellectual disability, autism spectrum disorder). * chemical dependency * currently taking the following medications: antidepressant, antipsychotic, and anti-seizures drugs.

Keywords: numeracy number sense